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Introduction
Cancer is a complex heterogeneous disease developing from 
integrated actions of multiple genetic and environmental factors 
through dynamic epigenetic and molecular regulatory 
mechanisms. One can find the complexity of cancer at the 
physiological cellular tissue and organ levels. There are 
interactions between tumours and their micro-environments, 
promoting their growth survival and the occurrence of distant 
metastasis [1]. However, the molecular mechanisms underlying 
these processes are poorly understood. It is reasonable to think 
that each cancer cell within a tumour might originate through 
different cancer-specific developmental mechanisms and 
mutations in distinct genes. There is increasing evidence that 
cancer initiation results from accumulative oncogenic mutations 
in long-lived stem cells or their immediate progenitor [2]. It is 
believed that signalling pathways, which regulate self-renewal in 
normal stem cells are deregulated in cancer-initiating cells, 
resulting in uncontrolled expansion and aberrant differentiation 
and formation of tumours with a heterogeneous phenotype [3]. 
The molecular changes within the tumour cells are followed by 
modification of the surrounding micro-environment. 
During the last few years the ‘omics’ revolution has dramatically 
increased the amount of data available for characterizing 
intracellular events. On the methodological level, most important 
for this development are differential gene expression analysis 
for recording mRNA concentration profiles and proteomics for 
providing data on protein abundance [4,5]. Soon after 
microarrays were introduced many researchers realized that the 
technique could be used to identify biologic markers associated 
with disease [6] and even with subclasses of disease [7–10]. As 
a result, a lot of patterns of expression were found that could be 
used to classify molecular subtypes of tumours [11] and predict 
the outcome [12–14] and response to treatment [15–17]. 
But the initial enthusiasm for the application of microarray 
technology was tempered by the publication of several studies, 
reporting contradictory results on the analysis of the same RNA 
samples hybridized on different microarray platforms. 
Scepticism arose regarding the reliability and the reproducibility 
of this technique. Most of the discrepancies were attributed to 
inconsistent sequence fidelity and annotation, low specificity of 
the spotted cDNA microarrays, lack of probe specificity for 
different isoforms or differences in the hybridization conditions, 
fluorescence measurement, normalization strategies and 
analytical algorithms applied [18–23]. One main source of the 
problem was also shown to be the small number of samples 
that were used to generate the gene lists of these experiments 
[24]. In view of these concerns raised on one hand and the 
great potential of this technology for tailored medicine on the 
other hand, the US Food and Drug Administration launched the 
Microarray Quality Control (MAQC) project, involving 137 
participants from 51 academic and industry partners to 
systemically address the technical reproducibility of microarray 
measurements within and between laboratories as well as 
across different microarray platforms. The results derived from 
this collaborative effort showed that the microarray 
measurements are highly reproducible within and across 
different microarray platforms, and that microarray technologies 
are sufficiently reliable to be used for clinical and regulatory 
purposes [25]. 
Currently, the main focus is on interlinking the various data 
sources generated by high-throughput array technologies [26]. 
There are two different ways of doing so: the systems biology 
approach and the biological networks. The approach of systems 
biological studies is to combine information from molecular 
biology genetics and epidemiology with comprehensive 
mathematical models to study how gene–gene interactions, 
gene–environment interactions and protein–protein interactions 
act together to cause disease [27]. On the other hand, the 
biological networks, also known as pathways, begin with the 
knowledge of known genes and proteins in an organism. In the 
next step, changes between normal and pathological systems 
are measured using either high-throughput techniques, such as 
gene expression microarrays for mRNAs or proteomics 
methods for protein concentrations [28,29]. A crucial part of this 
process is to model the inherent stochastic nature of the system 
[30–32]. This information on functional molecular interactions 
[33]—known as pathway databases—enriches our 
understanding of cellular systems [34]. Although the biological 
networks and systems biology approaches are very similar, 
biological networks are based more on biochemical reactions 
and signalling interactions among active proteins. This dynamic 
network is called the ‘interactome’. Hence, they rely more 
heavily on systemic network analysis, and other data-mining 
techniques compared with systems biology, which emphasizes 
statistical learning [35]. 
Recently, systems biological research has been providing a 
framework for such integration. Various groups have applied 
network analysis to gene data sets associated with cancer. 
Jonsson and Bates reported very recently that proteins 
associated with cancer show an increased number of interacting 
partners in the interactome [36]. Wachi et al specifically 
investigated the role of the interactome of genes differentially 
regulated in lung cancer [37]. Tuck and colleagues analysed 



















transcriptional regulatory networks consisting of transcription 
factors and their target proteins [38]. Genes differentially 
regulated between acute myeloid leukaemia and acute 
lymphoblastic leukaemia were significantly closer in the network 
as compared to randomly generated gene lists. The analogous 
result was observed for genes differentially regulated in breast 
cancer patients. On a more general level Xu and Li showed that 
disease-associated genes as listed in the OMIM database [39] 
tend to interact with other disease-associated genes [40]. 
Advancing Clinico-Genomic Trials (ACGT), a project funded by 
the European Commission in the Sixth Framework Programme, 
goes far beyond the systems biologic approach and the 
biological network by the addition of integrating clinical data. 
The ultimate objective of the ACGT project is the provision of a 
unified technological infrastructure, which will facilitate the 
seamless and secure access and analysis of multi-level clinical 
and genomic data enriched with high-performing knowledge 
discovery operations and services. By doing so, it is expected 
that the influence of genetic variation in oncogenesis will be 
revealed, the molecular classification of cancer and the 
development of individualized therapies will be promoted, and 
finally, the in silico tumour growth and therapy response will be 
realistically and reliably modelled. Achieving these goals, ACGT 
will not only secure the advancement of clinico-genomic trials 
but will also achieve an expandable environment to other 
studies’ technologies and tools. 
The  vision of ACGT is to become a pan-European voluntary 
network connecting individuals and institutions to enable the 
sharing of data and tools and thereby creating a European-wide 
web of cancer clinical research. In achieving this objective, 
ACGT will: 
1.  deliver a European Biomedical GRID infrastructure, 
offering seamless mediation services for sharing data 
and data-processing methods and tools; 
2.  deliver advanced security tools, including anonymization 
and pseudonymization of personal data according to 
European legal and ethical regulations; 
3.  develop an ACGT Master Ontology and use standard 
clinical and genomic ontologies and metadata for the 
semantic integration of heterogeneous data (clinical 
imaging genomic proteomic metabolomic and other as 
well as open source data from the web);  
4.  develop an Ontology-Based Trial builder for helping to 
easily set up new clinico-genomic trials to collect clinical 
research and administrative data and to put researchers 
in the position to perform cross-trial analysis; 
5.  deliver data-mining services in order to support and 
improve complex knowledge discovery processes. 
The technological platform of ACGT will be validated in the 
concrete setting of clinical trials on Cancer. Pilot trials have 
been developed based on the presence of clear research 
objectives, raising the need to integrate data at all levels. This 
integrative view underlies the development of clinico-genomic 
models, showing that the combination of biomarkers and clinical 
factors are most relevant in terms of statistical fit and also more 
practically in terms of cross-validation predictive accuracy [41]. 
 
Clinical trials in cancer 
In Europe, there are a lot of ongoing clinical trials and studies 
related to cancer. These trials will guarantee the best available 
treatment for patients with cancer and will provide the highest 
level of quality control if done according to GCP criteria [42]. 
However, amongst the different hospitals involved, there is 
heterogeneity in the way patients’ data are documented. The 
most important parts of data management systems in clinical 
trials are the Case Report Forms (CRFs), which are designed to 
collect the required research and administrative data and the 
trial database to store these data. In many multi-centre trials, 
paper-based CRFs are still used today. From the participating 
hospitals, thousands of CRFs are sent to a central data facility 
where the data are entered into a trial database. This is very 
time consuming and error prone. Often, the clinical trial 
databases are in-house developments that have to be 
implemented from scratch for each new trial [43]. Today, the 
preferable systems are web-based remote data-entry systems, 
where the data are captured at the participating site and 
transferred electronically to the trial central data facility. Most of 
these management systems allow designing the trial and 
especially creating electronic CRFs by the trial chairmen without 
any informatics skills. But none of these systems use an 
ontology, resulting in clinical trial databases that do not 
comprise comprehensive metadata, and that are not 
standardized. It is highly problematic to use such data for further 
research analysis. These difficulties and limitations are 
pronounced in efforts to extend national clinical trials to 
international ones. 
It is obvious that current clinical trial methodologies are not 
exploiting the technological advances offered. In ACGT, an 
ontology-based trial management system will be developed to 
enable trial chairmen to set up interoperable clinical data 
management systems. The system is called the ‘Ontology-



















based Trial Management System of ACGT’ (ObTiMA ). ObTiMA 
consists of three parts: 
1. Trial  Builder. 
(a)  Trial Outline Builder (TOB).  
(i)  Including a graphical schema of the trial. 
(b)  CRF Creator (CC). 
2. Repository. 
3.  Patient Data Management System (PDMS). 
The Trial Builder is primarily used to build a new trial. The user 
will be guided by a Master Protocol for clinical trials to write the 
Trial Protocol to build a graphical schema of the trial and to 
create all CRFs that are needed for the trial. All legal and ethical 
requirements will be considered during this process and 
appropriate solutions provided. ObTiMA maintains and 
manages the planning preparation performance and reporting of 
clinical trials with emphasis on keeping up-to-date contact 
information for participants and tracking deadlines and 
milestones such as those for regulatory approval or the issue of 
progress reports. 
By creating new CRFs, the database for the trial will be 
automatically generated and is always ontology based, 
including comprehensive metadata. The advantage of 
integrating an ontology in the design process is the built-in 
semantic interoperability. Data collected with this system can be 
seamlessly integrated into a data integration framework like 
ACGT, using the same reference ontology. The integration of 
the ontology in the process of creating CRFs will automatically 
help to maintain the ontology and enhance the use of ontologies 
in clinical trials in the future. The ACGT Trial Builder will support 
a modular concept. According to the modularity, there is the 
need for a repository for trials and CRFs for reuse. The PDMS 
is the data management system of the trial used by participants 
of a trial via remote data entry (RDE). ObTiMA will be a 
component-based extendable application. 
Today, it is recognized that the key to individualizing treatment 
for cancer lies in finding a way to quickly ‘translate’ the 
discoveries about human genetics made by laboratory scientists 
into tools that physicians can use in making decisions about the 
best way to treat patients. This area of medicine that links basic 
laboratory study to clinical data, including the treatment of 
patients, is called translational research and is promoted by 
clinico-genomic trials running in ACGT. These clinico-genomic 
trials are scenario based and driven by clinicians. Today, two 
main clinico-genomic trials and an in silico experiment are 
interconnected within the ACGT project. The realization of these 
trials will act as benchmark references for the development and 
assessment of the ACGT technology. 
 
Clinicogenomic trials 
1.  The first clinico-genomic trial focuses on breast 
cancer and uses gene-expression profiling based on 
microarrays as well as genotyping technology to 
identify predictive markers of response/resistance for 
anthracyclines chemotherapy. 
2.  The second trial focuses on paediatric 
nephroblastoma (Wilms tumour) and addresses the 
treatment of these patients according to well-defined 
risk groups in order to achieve highest cure rates to 
decrease the frequency and intensity of acute and late 
toxicity and to minimize the cost of therapy. The main 
objective of this trial is to explore a pattern of auto-
antibodies against nephroblastoma-specific antigens 
as a new diagnostic and prognostic tool for the more 
individualized stratification of treatment. 
In silico oncology 
3. The  in silico oncology focuses on the development and 
evaluation of tumour growth and response to treatment. 
The aim is to develop an ‘oncosimulator’ and evaluate 
the reliability of in silico modelling as a tool for assessing 
alternative cancer treatment strategies especially in the 
case of combining and utilizing mixed clinical imaging 
and genomic/genetic information and data. 
 
Breast cancer 
Breast cancer (BC) is the commonest cancer in women in the 
world in both industrialized and developing countries. Over a 
million, women will be diagnosed with breast cancer worldwide 
in 2004 [44]. More than 40,000 women will die this year of 
metastatic breast cancer in the United States alone, and more 
than 200,000 new cases of cancer will be detected [45]. The 
mortality rate around the world especially in developing 
countries is much higher, making breast cancer a significant 
public health problem. 
Breast cancer is both genetically and histopathologically 
heterogeneous, and the mechanisms underling breast cancer 



















development remains largely unknown. Breast cancer patients 
diagnosed with the same stage of disease often have 
remarkably different responses to therapy and overall outcome. 
Even with the strongest prognostic indicators, such as lymph 
node status, oestrogen receptor expression and histological 
grade, it is not possible to accurately classify breast tumours 
according to their clinical behaviour. Therefore, most patients 
are routinely treated with an adjuvant chemotherapy or 
hormonal therapy to reduce the risk of distant metastases. 
However, 70–80% of patients receiving this aggressive 
treatment would have survived without it, and therefore suffered 
unnecessarily from accompanying side effects [46]. A molecular 
marker with predictive power for breast cancer is going to 
benefit almost three out of four women that receive aggressive 
chemotherapy treatment although they would have survived 
without it. 
Much progress has been made over the past decades in our 
understanding of the epidemiology clinical course and basic 
biology of breast cancer. Identified risk factors include: 
1.  Family history (genetics). Identified gene mutations 
represent a tiny fraction of all breast cancers, much 
less than 10% overall. But, if present, they confer 
considerable lifetime risk compared to the general 
population. 
2.  Reproductive and hormonal life, for example early 
menarche, no pregnancy or late age at first birth, late 
menopause hormonal factors, such as high levels of 
free oestrogen, long-term use of oral contraceptives or 
menopausal hormone replacement or other factors that 
increase life-time exposure to oestrogen. 
3.  Lifestyle, particularly diet and exposures to 
carcinogenic agents. 
The heterogeneity of both the disease and the causal factors 
makes the clinical assessment difficult. This difficulty is mainly 
attributable to the first 5–10 years since the long-term outcome 
is rather predictable after this time. The standard markers for 
the assessment are morphological (size infiltration, lymph node 
metastasis, etc) and molecular (oestrogen and progesterone 
receptors status and her2/Neu). Although very useful for the 
clinicians, they are ‘subjects to subjectivity’ and surely not good 
enough to make the therapeutic decision accurate. Global 
expression analysis using microarrays now offers 
unprecedented opportunities to obtain molecular signatures of 
the state of activity of diseased cells and patient samples. This 
groundbreaking approach to studying cancer promises to 
provide a better understanding of the underlying mechanism for 
tumorgenesis, more accurate diagnosis, more comprehensive 
prognosis and more effective therapeutic interventions. Given 
the clinical heterogeneity of breast cancer microarrays it is an 
ideal tool to establish a more accurate classification [47]. But 
the question of whether these signatures are a better prognostic 
tool on adjuvant decision making than traditional 
clinico/pathological factors is still unanswered. 
Using the preoperative approach combined with microarray and 
proteomics analysis of pre- and post-treatment biopsies, the 
TOP and FRAGRANCE multi-centre trials both coordinated by 
the Jules Bordet Institute (ACGT partner) aim to identify novel 
molecular markers/signatures predictive of response/resistance 
to anthracycline-based chemotherapy and endocrine therapy, 
respectively. Currently, TRANSBIG, a newly created 
translational research network affiliated with the Breast 
International Group (BIG), launched an innovative worldwide 
clinical trial, aiming to evaluate the prognostic value of the 70-
gene signature identified by the Amsterdam group [14]. The 
MINDACT trial will test the hypothesis that gene classification 
based on the gene expression profiles of adjuvant breast cancer 
patients may allow for significant reduction in adjuvant 
chemotherapy prescription compared with the traditional 
methods. 
The management of metastatic breast cancer has also evolved 
and improved over the last few decades [48]. Today, therapy 
decision making involves the consideration of many clinical 
parameters. Making the correct pathological diagnosis is always 
preferred before the initiation of treatment of the cancer patient, 
because it would facilitate the individualization of treatment and 
also because of the fact that cancer tends to become more 
aggressive as time passes by. Using standard pathological 
techniques, it is estimated that up to 5–10% of all tumours may 
actually be misclassified [49, 50]. 
There are two basic scenarios foreseen for the realization of the 
breast cancer clinico-genomic trials: 
1.  BC-scenario 1 – Chemotherapeutic treatment: a 
chemotherapy assessment scenario addressing the 
treatment of breast cancer patients based on the 
molecular characterization of pre- and meta-surgical 
chemotherapy response. The goal is to induce breast 
cancer chemotherapeutic treatment strategies and drug 
administration alternatives on the basis of patients’ 
individual clinico-genomic profiles. Furthermore, an 
additional aim is to form and validate respective clinico-




















Figure 1: Breast cancer clinico-genomic trials—‘entry point’ of the clinico-genomic trial is realized by access to the ACGT environment, 
integrating relevant data sources from remote sites in order to retrieve patients’ data that meet specified clinico-genomic/genotypic profiles 
‘first and second decision points’ are also supported by ACGT, induction and assessment of pre- and post-surgical treatment and molecular 
signatures for the prognosis classification of breast cancer patients (a line for knowledge-discovery and clinical decision-making research), 
‘molecular analysis’ is also supported by ACGT in order to ease exploration and induction of fundamental molecular knowledge (gene 
expression profiling, comparative genomics, proteinomics, etc).
genomic breast cancer treatment guidelines and drug-
administration protocols. 
2.  BC-scenario 2 – Decision making: a decision-making 
scenario addressing the operational workflows involved 
in the course of managing breast cancer patients, i.e. 
identification of relative guidelines and best-practice 
protocols being induced and validated by the 
aforementioned BC-Scenario 1 above. In other words, it 
presents a scenario of how the outcome and results of 
clinico-genomic trials are utilized in the course of normal 
clinical decision making. The aim is to form evaluate and 
validate the involved decision-making processes as 
realized and offered by the integrated ACGT 
environment and platform (Figure 1). 
 
Nephroblastoma 
Wilms tumour (nephroblastoma) is the most common malignant 
renal tumour in children. Dramatic improvements in survival 
have occurred as the result of advances in anaesthetic and 
surgical management, irradiation and chemotherapy and the 
enrolment of nearly all patients with this disease in clinical trials 
for more than 30 years. Today, treatments are based on several 
multi-centre trials and studies conducted by the International 
Society of Paediatric Oncology (SIOP) in Europe and Children’s 
Oncology Group (COG) in Northern America. The main 
objectives of these trials and studies are to treat patients 
according to well-defined risk groups in order to achieve highest 
cure rates, to decrease the frequency and intensity of acute and 
late toxicity, and to minimize the cost of therapy. In that way, the 



















  SIOP trials and studies largely focus on the issue of 
preoperative therapy. The concept of neoadjuvant 
chemotherapy plays an important role in the treatment for most 
paediatric solid tumours today. The complete surgical removal 
of a shrunken tumour is facilitated, and mutilation caused by 
surgical procedures is minimized or avoided and micro-
metastases not visible at diagnosis are treated as early as 
possible. Besides, the response to treatment can be measured 
individually by tumour volume reduction and/or percentage of 
therapy-induced necrosis in the histological specimen. 
The International Society of Paediatric Oncology enrolled 
children with Wilms tumour in six studies up to now (SIOP 1, 
SIOP 2, SIOP 5, SIOP 6, SIOP 9, SIOP 93-01). The seventh 
trial and study (SIOP 2001) started in 2002 and is still recruiting 
patients. A review of the SIOP studies is given by Graf et al [51]. 
Since 1994, more than 1500 patients with a kidney tumour are 
enrolled in the SIOP studies and trials in Germany. Today, more 
than 90% of patients with Wilms tumour can be cured, as shown 
for stage I patients in the trial SIOP 93-01 [52]. 
The challenges and the main motivation for deploying the SIOP 
nephroblastoma trial within ACGT are: 
1.  The distributed nature of the participating clinical sites: 
there are more than 200 hospitals treating children with 
nephroblastoma according to the same SIOP protocol. 
These hospitals are mainly located around Europe and 
few are elsewhere in the world. There is a clear need to 
seamlessly integrate data from all these sites. 
2.  The fact that microarray-based research is still not 
included in any nephroblastoma trial: although both the 
SIOP and the COG are promoting the use of microarray 
analysis to enhance clinical trials, there is a need to 
integrate clinico-genomic data in order to investigate 
prognostic factors and assess the potential of 
individualized therapy. The ACGT promotes this 
integration and provides the necessary analytic tools 
and standards for clinical trials. 
3.  Heterogeneity of data: data collected are: images of the 
tumour at different time points related to the treatment, 
information about treatment itself (surgery, 
chemotherapy and irradiation), data regarding acute 
toxicity and late effects, information about relapse and 
outcome, and microarray data and other molecular 
genetic data for a limited set of patients. 
The ACGT will promote the integration of all this information to 
facilitate further molecular analysis access to tissue banks,
provide the necessary analytic tools and allow clinicians to 
efficiently analyse data that are presently communicated by mail 
or maintained in flat text files at various remote clinical sites. 
In the SIOP trials, the diagnosis is done by imaging studies 
alone before starting preoperative chemotherapy. A definitive 
diagnosis is available after histological proof after surgery of the 
tumour. As a disadvantage, 1% of children receive 
chemotherapy whilst having a benign disease. In this respect, 
the ACGT nephroblastoma trial is based on one scenario that is 
highly important for helping to assure the correct diagnosis 
before starting any kind of treatment. 
Wilms-scenario: tumour-specific antigens  
Immunogenic tumour-associated antigens have been reported 
for a variety of malignant tumours, including brain tumours and 
prostate, lung and colon cancer [53 54]. In a first step, 
immunogenic Wilms tumour-associated antigens will be 
identified by immuno-screening of a cDNA expression library. 
This first step will identify those antigens that show reactivity 
against serum antibodies of patients with Wilms tumour and not 
with healthy individuals. They will be characterized using web 
databases (Table 1). Only these antigens will be used in step 2 
of the scenario, where serum from a specific patient will be 
tested against these newly identified Wilms tumour antigens. As 
a result, a specific pattern of antigens will be found in each 
patient and correlated to the histological subtype of the tumour, 
the gene expression profiling of the tumour, the response to 
chemotherapy and the outcome of the patient (Figure 2). 
The pattern of the identified antigens will contribute to 
answering key questions about the humeral immune response 
in Wilms tumour patients:  
1.  Are Wilms tumours associated with frequent antibody 
response? 
2.  Is there a complex and/or specific antibody response? 
3.  Is this response associated with specific genetic 
features, like gene amplifications or DNA losses? 
4.  Do these immunogenic antigens share common features 
like specific sequence motives? 
5.  Does the seroreactivity pattern allow early identification 
of Wilms tumours and also their histological subtypes? 
6.  Does the seroreactivity pattern represent a prognostic 
marker for Wilms tumours in respect to 
chemotherapeutic response and/or outcome? 



















 Table 1: Data available from websites 
 
In silico oncology 
Currently, cancer treatment decision and planning is based to a 
large extent on the disease behaviour of the statistically ‘mean’ 
patient rather than on the behaviour of each individual case. 
Therefore, critical details of the particular patient’s tumour 
biology, such as gene expression profile in conjunction with 
imaging data, are largely ignored. To alleviate this deficiency, 
ACGT will develop patient individualized tumour growth and 
tumour and normal tissue response-simulation models 
concerning breast cancer and nephroblastoma. Furthermore, 
the  in silico application will demonstrate the flexibility of the 
ACGT environment and its potential to become an European 
platform for both conducting clinical trials and implementing 
demanding applications. The in silico oncology systems under 
development will serve as basic research tools in the cancer 
integrative biology arena [55,56]. 
From a clinical point of view, six different simulation 
experiments have to be developed from In Silico Oncology. 
These models should answer the following questions for an 
individual patient [57]: 
1.  What is the natural local tumour growth over time in size 
and shape? 
2.  When and whereto is a tumour metastasising? 
3.  Can the response of the local tumour and the 
metastases to a given treatment be predicted in size and 
shape over time? 
4.  What is the best treatment schedule for a patient 
regarding drugs, surgery, irradiation and their 
combination, dosage, time schedule and duration? 
5.  Is it possible to predict severe adverse events (SAE) of 
a treatment and to propose an alternative treatment to 
avoid them without deteriorating outcome? 
6.  Is it possible to predict a cancer before it occurs and to 
recommend a treatment that will prevent the occurrence 
or a recurrence of a cancer in an individual patient? 




















Figure 2: Schematic description of the scenario.




















The aim to develop an ‘oncosimulator’ within ACGT is to 
evaluate the reliability of in silico modelling as a tool. In silico 
oncology always has to be tested in the setting of clinico-
genomic trials to prove the expectations for getting better 
individualized cancer treatments with higher cure rates and less 
acute and late toxicity. In silico oncology using and combining 
clinical imaging and genomic/genetic data will give doctors a 
better way to tailor cancer treatment; thus holding the promise 
of applying a more individualized treatment with increasing 
survival, reducing side effects and improving the quality of life. 
Additionally, it is a platform for better understanding and 
exploring the natural phenomenon of cancer, as well as training 
doctors and interested patients alike. 
Although most patients with cancer respond to therapy, not all 
of these are cured. Even objective clinical responses to a given 
treatment do not translate into substantial improvements in 
overall survival. The reason for this phenomenon can be 
explained by the fact that therapies successfully eliminating the 
vast majority of cancer cells may be ineffective against rare 
biologically distinct cancer stem cells. Therefore, new methods 
for assessing treatment efficacy have to be developed as a 
traditional response criteria, such as the RECIST criteria, and 
their further developments [58, 59, 60] measure tumour bulk do 
not reflect changes in the rare cancer stem cells [61]. It seems 
obvious that treatment effective against the gross majority of 
differentiated cancer cells is ineffective for rare cancer stem 
cells. This suggests that treatment should be changed when a 
patient is in clinical remission, following the destruction or 
removal of the bulky tumour burden. In silico experiments 
should focus on this topic. Data on cancer stem cells for each 
tumour have to be created by molecular biologists, and 
clinicians have to provide them with tumour material. This again 
underlines the importance of enrolling patients into clinico-
genomic trials if in silico experiments are carried out and 
conclusive results are awaited. 
In order to achieve all of these goals, in silico oncology has to 
undergo a thorough clinical optimization and validation process. 
Nephroblastoma and breast cancer have been discussed to 
serve as two paradigms to clinically specify and evaluate the 
‘oncosimulator’ as well as the emerging domain of in silico 
oncology. 
The ‘oncosimulator’ is based on the ‘top-down’ multi-scale 
simulation strategy developed by the In Silico Oncology Group 
National Technical University of Athens (www.in-silico-
oncology.iccs.ntua.gr) [62–65]. The imaging histopathological 
molecular and clinical data of any given patient following 
pertinent pre-processing are introduced into the Tumour and 
Normal Tissue Response Simulation Module, which executes 
the simulation code for a defined candidate treatment scheme 
(Figure 3). The prediction is judged by the clinician, and further 
schemas can be done in an analogous way. Finally, the clinician 
decides on the optimal treatment scheme to be administered to 
the patient based on his or her formal medical education and 
knowledge and the predictions of the ‘oncosimulator’ after 
retrospective and prospective validation. 
 
Legal and ethical aspects 
In the context of medical research involving patients, the ethical 
principle of autonomy is generally recognized as one of the 
most basic principles. Derived from autonomy, the doctrine of 
informed consent has been widely acknowledged [66,67]. 
However, clinico-genetic research addresses new questions 
because data are collected and used not only for specific 
research questions but also for future research projects, which 
cannot be defined at the time consent is requested [68]. 
Furthermore, research results may be obtained, which could be 
important for individual patients or groups of individuals (e.g. 
family members). Facing these new demands doubts have been 
raised concerning the applicability of the doctrine of informed 
consent in its current form. 
Research projects can only succeed if it is possible to create a 
framework that takes into account the needs of modern 
scientific genetic research and the needs of the patients 
regarding data protection and privacy. Only if these two 
conditions are met can such research projects succeed. In 
ACGT, participants will be provided with adequate and 
understandable information regarding data sampling, storage 
and usage. The given information for informed consent must 
always include: 
1.  the main intentions of ACGT; 
2.  the voluntariness of participation in the research; 
3.  the range of how data are used; 
4.  the measures that are taken to protect the personal 
rights of donors; 
5.  the possible risks and benefits of the research; 
6.  further implications of participation. 




















Figure 3: A block diagram of the oncosimulator’s function.
In ACGT, a tiered consent will be used referring to clinico-
genomic research on cancer in the context of the specific 
structure of the project. Informed consent is necessary for 
patients participating in ACGT trials and for authorized users of 
the ACGT grid structure before getting access. They have to 
declare that they will meet the requested standards of ACGT 
regarding the protection of data and privacy.  
Since clinico-genomic research may yield individually important 
research results, the question of whether and under what 
circumstances data should or must be fed back to the patients 
concerned has to be discussed. It is widely acknowledged that 
general study findings must be accessible for patients involved 
[69,70]. Furthermore, anybody has the right to access personal 
data stored about him or her. But the right to access such data, 
which is based on ethical principles as well as on legal
provision, is a passive one. Therefore, the implementation of 
this right requires an organizational structure that is suitable to 
reply to donors’ requests. Additionally, it is recommended that 
ACGT provides the technical and organizational means for 
individual feedback processes of such results initiated by the 
investigator. The only way to enable investigator-driven 
individual feedback processes—and to allow individual donors 
to withdraw consent—is the pseudonymization of data. 
Therefore, the process of feeding back individually relevant data 
requires technical mechanisms to guarantee data retrieval by 
those donors who ask for individual feedback. Nevertheless, the 
discussion what kind of data can be fed back is controversial, 
since the relevance of data is not easy to define [71,72]. From 
an ethical point of view, it is therefore recommended to give the 
patients the option to decide about feedback of personal data 
and allow them to withdraw their consent. Every individual 



















feedback process should also be accompanied by consultation. 
Given the complexity of the ethical aspects regarding the 
disclosure and feedback, a multi-lingual internet-based 
information service for donors will be established within ACGT. 
As genetic data are very sensitive data, which hold information 
not only about the data subject itself but also about his or her 
relatives’ possible diseases, etc, the processing of this kind of 
data is only possible under special requirements. Genetic data 
are also very vulnerable and can only be de-facto anonymized, 
which means that—at least in theory—a re-identification is 
always possible if matching information from the genetic code of 
that of a known person. This is the big difference to normal 
conventional data and a challenge for the application of data 
protection regulation. 
The data protection structure to be established for ACGT has to 
find a balance for the two competing aims of modern genetic 
research and the data protection needs of the participating 
patients. In order to comply with current data protection 
legislation, it is recommended that as much of the patient’s 
genetic data as possible is (de-facto) anonymized. As long as 
there is no link between de-facto anonymized genetic data and 
the data subject, they can be regarded as anonymous and can 
be kept outside of the scope of the Data Protection Directive 
95/46/EC [73]. Following that the Data Protection Directive is 
applicable whenever the particular data controller has the link 
from the genetic data to the concerned data subject or 
whenever he can get this link with legal means or whenever a 
third party can establish this link. Therefore, the genetic data 
have to be regarded as personal data in the case of transfer 
and disclosure. In all other cases of data processing, for 
example usage and storage, the Data Protection Directive is not 
applicable as long as the data controller has no legal access to 
the link. Besides that, an informed consent of the participating 
patients is needed because of ethical reasons and as a fallback 
solution for the legal data protection framework [74]. 
Furthermore, a data protection framework has to be set up for 
ACGT, which consists mainly of three parts. First, an ACGT 
Data Protection Board has to be implemented. It will be the 
central data controller within ACGT as well as a legal body able 
to conduct contracts regarding data protection on behalf of 
ACGT. Second, a Trusted Third Party is needed in this data 
protection framework, which is responsible for the 
pseudonymization of the patient’s genetic data, and which will 
also be the keeper of the pseudonymization key to re-identify 
the patient concerned. Therefore, the patient’s genetic data is 
de-facto anonymous for users and participants of ACGT not 
having the link. Third, contracts between all participating 
hospitals research units or other users of the genetic data and 
ACGT must be concluded in order to ensure confidentiality data 
security and compliance with data protection legislation. 
By implementing this framework, the needs of the researchers 
hospitals and patients can be satisfied at the same time so that 
the  ACGT Data Protection Framework is a milestone to lead 
ACGT to success. It allows participating researchers to 




During the last few years, the ‘omics’ revolution has dramatically 
increased the amount of data available for characterizing 
intracellular events. As a result, a lot of patterns of gene 
expression were found that could be used to classify molecular 
subtypes of tumours and predict the outcome and response to 
treatment. Currently, the main focus is on interlinking the 
various data sources generated by high-throughput array 
technologies. Various groups have applied network analysis to 
gene data sets associated with cancer. ACGT, a project funded 
by the European Commission in the Sixth Framework 
Programme, goes far beyond these networks by the integration 
of clinical data. The ultimate objective of the ACGT project is 
the provision of a unified technological infrastructure, which will 
facilitate the seamless and secure access and analysis of multi-
level clinical and genomic data enriched with high-performing 
knowledge discovery operations and services. By doing so, it is 
expected that the influence of genetic variation in oncogenesis 
will be revealed, the molecular classification of cancer and the 
development of individualized therapies will be promoted, and 
finally, the in silico tumour growth and therapy response will be 
realistically and reliably modelled. Achieving these goals, ACGT 
will not only secure the advancement of clinico-genomic trials, 
but will also achieve an expandable environment to other 
studies’ technologies and tools. 
Today, it is recognized that the key to individualizing treatment 
for cancer lies in finding a way to quickly ‘translate’ the 
discoveries about human genetics made by laboratory scientists 
into tools that physicians can use in making decisions about the 
best way to treat patients. This area of medicine that links basic 
laboratory study to clinical data, including the treatment of 
patients, is called translational research and is promoted by 
clinico-genomic trials running in ACGT. These clinico-genomic 
trials are scenario based and driven by clinicians. Today, two 
main clinico-genomic trials and an in silico experiment are 
interconnected within the ACGT project. The realization of these 



















trials will act as benchmark references for the development and 
assessment of the ACGT technology. 
All ethical and legal requirements for clinico-genomic trials will 
be respected. A data protection framework will be set up for 
ACGT, which consists of an ACGT Data Protection Board, a 
Trusted Third Party responsible for the pseudonymization of the 
patient’s data and contracts between all participating hospitals 
research units or other users of genetic data. 
Patients who take part in clinico-genomic trials may be helped 
personally by the treatment(s) they receive. They get up-to-date 
care from cancer experts, and they receive either a new 
treatment being tested or the best available standard treatment 
for their cancer. Of course, there is no guarantee that a new 
  treatment being tested or a standard treatment will cure the 
patient. New treatments also may have unknown risks, but if a 
new treatment proves effective or more effective than standard 
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